These studies also showed that losartan, an angiotensin II receptor antagonist used in the treatment of hypertension, can block in vitro CCL2- and OS cell–elicited monocyte recruitment through noncompetitive inhibition of CCL2-induced ERK1/2 activation, independent of angiotensin II receptor signaling. This evidence concerns the gene CCL2 and hypertensive disorder.